Preliminary results suggest that treatment for rare disease is safe, but its effectiveness is unclear. A therapy that edits genes directly in the human body might be safe, suggest early findings from the first trial to test the approach. Researchers from Sangamo Therapeutics in Richmond, California, designed enzymes to correct an error in the genome...